Miller A R, Lalonde C E, McGrail K M, Armstrong R W
Department of Pediatrics, University of British Columbia, and the Children's and Women's Health Centre of British Columbia, Vancouver.
CMAJ. 2001 Nov 27;165(11):1489-94.
There are concerns about the frequency and appropriateness of psychostimulant drug prescription to children. In order to identify unusual or unexpected patterns of use or prescribing, we reviewed prescription of methylphenidate (Ritalin) to children and adolescents aged 19 years or less in British Columbia between 1990 and 1996.
We obtained information about patients, physicians and prescriptions from British Columbia's Triplicate Prescription Program database for controlled drugs. Prescription data were available for the period Jan. 1, 1990, to Dec. 31, 1996. Linkage with the BC Linked Health Dataset provided additional demographic and health information.
In 1990, 1715 children received at least 1 prescription for methylphenidate (1.9 per 1000 children). By 1996, the number had increased to 10,881 children (11.0 per 1000). Because some children were prescribed methylphenidate in more than 1 year, we also calculated the frequency with which the drug was prescribed to children who had never received it before. This rate increased from 1.0 per 1000 children in 1990 to 4.7 per 1000 in 1995; the rate fell in 1996 to 3.5 per 1000. The number of children receiving methylphenidate varied across health regions of the province, from 12.0 to 35.4 per 1000. Use also varied by socioeconomic status quintile: in the 2 lowest (least privileged) quintiles, 21.6 per 1000 children received methylphenidate, compared with 18.4 per 1000 in the 3 highest quintiles (relative risk 1.2, 95% confidence interval 1.1-1.2). Pediatricians and psychiatrists wrote 23% and 21% of all prescriptions respectively. General practitioners accounted for 56% of all prescriptions and 41% of initial methylphenidate prescriptions. A claim for prior specialist consultation was found in 30% of such cases. Many of the children who received more than 10 prescriptions had seen 4 or more physicians. The average daily dosage prescribed differed little among general practitioners, pediatricians and psychiatrists, unlike the mean interval between successive prescriptions: 89.9 (standard deviation [SD] 68.2), 99.8 (SD 64.1) and 75.9 (SD 70.2) days respectively. Persistence with therapy was more likely when a psychiatrist provided the initial prescription, or with involvement of more than one specialty.
Many trends and practices in the prescription of methylphenidate to children in British Columbia are consistent with other settings and accepted standards. Some aspects warrant closer investigation, including regional and socio-economic discrepancies in the distribution of patients, the relative involvement of primary and specialist care providers, continuity of care issues and time intervals between prescriptions.
人们对儿童使用精神振奋药物处方的频率及合理性存在担忧。为了识别异常或意外的使用或处方模式,我们回顾了1990年至1996年间不列颠哥伦比亚省19岁及以下儿童和青少年的哌甲酯(利他林)处方情况。
我们从不列颠哥伦比亚省的管制药品三联处方项目数据库中获取了有关患者、医生和处方的信息。处方数据涵盖1990年1月1日至1996年12月31日期间。与不列颠哥伦比亚省关联健康数据集的链接提供了更多人口统计学和健康信息。
1990年,1715名儿童至少接受过1次哌甲酯处方(每1000名儿童中有1.9人)。到1996年,这一数字增至10881名儿童(每1000名中有11.0人)。由于一些儿童在不止一年中被开了哌甲酯,我们还计算了之前从未接受过该药治疗的儿童的用药频率。这一频率从1990年的每1000名儿童中有1.0人增加到1995年的每1000名中有4.7人;1996年降至每1000名中有3.5人。该省各健康区域接受哌甲酯治疗的儿童数量有所不同,每1000人中有12.0至35.4人。使用情况也因社会经济地位五分位数而异:在最低的两个(最贫困)五分位数中,每1000名儿童中有21.6人接受哌甲酯治疗,而在最高的三个五分位数中,每1000名中有18.4人(相对风险1.2,95%置信区间1.1 - 1.2)。儿科医生和精神科医生分别开具了所有处方的23%和21%。全科医生占所有处方的56%,占哌甲酯初始处方的41%。在30%的此类病例中发现有之前专科会诊的记录。许多接受超过10次处方的儿童看过4名或更多医生。全科医生、儿科医生和精神科医生开出的平均每日剂量差异不大,而连续处方之间的平均间隔时间不同:分别为89.9(标准差[SD]68.2)、99.8(SD 64.1)和75.9(SD 70.2)天。当初始处方由精神科医生开具或有多个专科参与时,坚持治疗的可能性更大。
不列颠哥伦比亚省儿童哌甲酯处方的许多趋势和做法与其他地区及公认标准一致。一些方面值得进一步调查,包括患者分布的区域和社会经济差异、初级和专科护理提供者的相对参与情况、护理连续性问题以及处方之间间隔时间。